The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult population suffers the disease. Dapagliflozin is an inhibitor of the sodium-glucose co-transporter SGLT2 in the kidney and is a novel treatment for diabetes type 2. Some studies indicate that SGLT2 inhibitors have benefits on blood pressure, triglycerides levels and help to raise the levels of high density lipoproteins cholesterol (c-HDL). The aim of this study is to evaluate the effect of dapagliflozin on metabolic syndrome, insulin sensitivity and insulin secretion. The investigators hypothesis is that the administration of dapagliflozin modifies the metabolic syndrome, insulin sensitivity and insulin secretion.
A randomized, double-blind, placebo-controlled clinical trial its going to carry out in 24 patients with a diagnosis of metabolic syndrome in accordance with the International Diabetes Federation (IDF). Waist circumference, glucose, insulin levels, lipid profile, creatinine and acid uric are going to be load after a 75 g of dextrose load. 12 patients will receive Forxiga (dapagliflozin), 10 mg, one per day before breakfast during 3 months. The remaining 12 patients will receive placebo at the same dose. There will be calculated Area Under the Curve of glucose and insulin, total insulin secretion (insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin sensitivity (Matsuda index). This protocol it's already approved by the local ethics committee and written informed consent it's going to be obtained from all volunteers. Results will be presented as mean and standard deviation. Intra and inter group differences are going to be tested using the Wilcoxon signed-rank and Mann-Whitney U-test respectively; p≤0.05 it's going to be considered significant.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
24
Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
Placebo capsules, 10 mg, one per day before breakfast during 90 days.
Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara
Guadalajara, Jalisco, Mexico
Waist Circumference at Week 12.
The waist circumference is going to be evaluated at week 12 with a flexible tape with standardized techniques.
Time frame: Week 12
Triglycerides Levels at Week 12.
The triglycerides levels are going to be evaluated at week 12 with enzymatic-colorimetric techniques.
Time frame: Week 12
High Density Lipoprotein (c-HDL) Levels at Week 12.
The c-HDL levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques.
Time frame: Week 12
Glucose Levels at Minute 0 at Week 12.
The fasting glucose (0') levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques.
Time frame: Week 12
Systolic Blood Pressure at Week 12.
The systolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer.
Time frame: Week 12
Diastolic Blood Pressure at Week 12.
The diastolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer.
Time frame: Week 12
Insulinogenic Index (Total Insulin Secretion) at Week 12.
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus. Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion at week 12.
Time frame: Week 12
Stumvoll Index (First Phase of Insulin Secretion) at Week 12.
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis. First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the frst phase of insulin secretion at week 12.
Time frame: Week 12
Matsuda Index (Total Insulin Sensitivity) at Week 12.
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index \[10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)\]. The entered values reflect the insulin sensitivity at week 12.
Time frame: Week 12
Body Weight at Week 12.
The weight it's going to be measured at week 12 with a bioimpedance balance.
Time frame: Week 12
Body Mass Index at Week 12
The Body Mass index it's going to be calculated at week 12 with the Quetelet index.
Time frame: Week 12
Fat Mass at Week 12.
The fat mass is going to be evaluated at week 12 through bioimpedance.
Time frame: Week 12
Total Cholesterol at Week 12
The total cholesterol will be estimated by standardized techniques at week 12.
Time frame: Week 12
Low Density Lipoproteins (c-LDL) at Week 12
The c-LDL levels are going to be measured at week 12 with standardized techniques.
Time frame: Week 12
Alanine Aminotransferase (ALT) at Week 12.
The ALT hepatic transaminase levels are going to be measured at week 12 with standardized techniques.
Time frame: Week 12.
Aspartate Aminotransferase (AST) at Week 12.
The hepatic transaminase AST will be evaluated with standardized methods at week 12
Time frame: Week 12
Creatinine at Week 12.
The creatinine levels are going to be measured at week 12 with standardized techniques.
Time frame: Week 12.
Uric Acid at Week 12.
The uric acid levels are going to be measured at week 12 with standardized techniques.
Time frame: Week 12.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
AUC of Glucose at Week 12.
The AUC of glucose will be calculated from the glucose values obtained from the minuted oral glucose tolerance curve at week 12
Time frame: Week 12
AUC of Insulin at Week 12.
The AUC will be calculated from the insulin values obtained from the minuted oral glucose tolerance curve at week 12
Time frame: Week 12
Glucose at Minute 30 at Week 12.
The glucose at minute 30 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve
Time frame: Week 12
Glucose at Minute 60 at Week 12.
The glucose at minute 60 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve
Time frame: Week 12
Glucose at Minute 90 at Week 12.
The glucose at minute 90 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve
Time frame: Week 12
Glucose at Minute 120 at Week 12.
The glucose at minute 120 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve
Time frame: Week 12